ReviewFrontiers in endocrinology2019
Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Statins and thyroid eye disease (TED): a systematic review.Endocrine · 2024Pooled it
- Impacts of physical, metabolic, and immunological factors on the exophthalmometry values of a contemporary Japanese population with/without Graves' disease.Endocrine journal · 2026Article
- Analysis of non-cholesterol sterols and fatty acids in patients with graves' orbitopathy: insights into lipid metabolism in relation to the clinical phenotype of disease.Journal of endocrinological investigation · 2025Article
- Orbital Radiotherapy for Graves' Ophthalmopathy: Single Institutional Experience of Efficacy and Safety.Diseases (Basel, Switzerland) · 2025Article
- The relationship between cholesterol levels and thyroid eye disease.European thyroid journal · 2025Article
- Simvastatin-Induced Ferroptosis in Orbital Fibroblasts in Graves' Ophthalmopathy.Investigative ophthalmology & visual science · 2025Article
- Assessment of disease activity in Graves' orbitopathy.Frontiers in ophthalmology · 2025Review
- Temporal trends in the clinical presentation of Graves' orbitopathy: a single-center retrospective study.Journal of endocrinological investigation · 2024Article
- Predicting glucocorticoid effectiveness in thyroid eye disease: combined value from serological lipid metabolism and an orbital MRI parameter.European thyroid journal · 2024Article
- Thyroid-associated ophthalmopathy: the role of oxidative stress.Frontiers in endocrinology · 2024Review
- Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study.Frontiers in endocrinology · 2024Article
- A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves' orbitopathy.Frontiers in genetics · 2024Article
- Exploring gut microbiota and metabolite alterations in patients with thyroid-associated ophthalmopathy using high-throughput sequencing and untargeted metabolomics.Frontiers in endocrinology · 2024Article
- Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.Frontiers in endocrinology · 2024Review
- Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.International ophthalmology · 2023Review
- Identification of optimal feature genes in patients with thyroid associated ophthalmopathy and their relationship with immune infiltration: a bioinformatics analysis.Frontiers in endocrinology · 2023Article
- Novel Insight into Non-Genetic Risk Factors of Graves' Orbitopathy.International journal of environmental research and public health · 2022Article
- Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy.European thyroid journal · 2022Article
- The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.Biomedicines · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' Orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves' disease (GD). Its ultimate cause remains unclear, but it is commonly considered an autoimmune disorder due to self recognition of autoantigens constitutively expressed by orbital fibroblasts (OFs), and thyroid epithelial cells. High dose intravenous glucocorticoids (ivGC) are the most commonly used treatment for moderately severe and active GO. However, based on the complex pathogenesis of GO, a number of factors may have a protective and maybe a therapeutic role. The use of other medications improving the effect of GC may increase the overall effectiveness of the therapy and reduce GC doses, thereby limiting side effects. Recently, a possible protective role of 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, the so-called statins, and perhaps of lowering cholesterol levels, has been proposed. Thus, statins have been reported to be associated with a reduced frequency of GO in GD patients and in recent cross-sectional and retrospective studies a significant correlation was found between the occurrence of GO and both total and LDL-cholesterol in patients with a GD of relatively recent onset, suggesting a role of cholesterol in the development of GO. Moreover, a correlation was found between the GO clinical activity score and total as well as LDL-cholesterol in untreated GO patients, depending on GO duration, indicating a role of cholesterol on GO activity. Therefore, statin treatment may be beneficial for GO. Here we review this subject, which offers new therapeutic perspectives for patients with GO.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.